These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1305 related items for PubMed ID: 10601505
1. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. N Engl J Med; 1999 Dec 16; 341(25):1865-73. PubMed ID: 10601505 [Abstract] [Full Text] [Related]
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA. N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227 [Abstract] [Full Text] [Related]
3. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group Study A5095 Team. N Engl J Med; 2004 Apr 29; 350(18):1850-61. PubMed ID: 15115831 [Abstract] [Full Text] [Related]
4. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. AIDS; 2008 Jan 11; 22(2):275-9. PubMed ID: 18097230 [Abstract] [Full Text] [Related]
5. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA, AIDS Clinical Trials Group 364 Study Team. N Engl J Med; 2001 Aug 09; 345(6):398-407. PubMed ID: 11496850 [Abstract] [Full Text] [Related]
6. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538 [Abstract] [Full Text] [Related]
7. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK, Study 934 Group. N Engl J Med; 2006 Jan 19; 354(3):251-60. PubMed ID: 16421366 [Abstract] [Full Text] [Related]
8. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM. N Engl J Med; 1999 Dec 16; 341(25):1874-81. PubMed ID: 10601506 [Abstract] [Full Text] [Related]
10. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team. JAMA; 2001 Mar 07; 285(9):1155-63. PubMed ID: 11231744 [Abstract] [Full Text] [Related]
11. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP. N Engl J Med; 1998 Oct 29; 339(18):1269-76. PubMed ID: 9791142 [Abstract] [Full Text] [Related]
12. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M. AIDS; 2000 Jul 28; 14(11):1591-600. PubMed ID: 10983646 [Abstract] [Full Text] [Related]
13. Efavirenz in HIV infection. Casado JL, Moreno S. N Engl J Med; 2000 Apr 27; 342(17):1290-1. PubMed ID: 10787332 [No Abstract] [Full Text] [Related]
14. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM, Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. N Engl J Med; 2003 Sep 11; 349(11):1036-46. PubMed ID: 12968087 [Abstract] [Full Text] [Related]
15. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Cahn P, Vibhagool A, Schechter M, Soto-Ramirez L, Carosi G, Smaill F, Jordan JC, Pharo CE, Thomas NE, Steel HM. Curr Med Res Opin; 2004 Jul 11; 20(7):1115-23. PubMed ID: 15265256 [Abstract] [Full Text] [Related]
16. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent]. Allerg Immunol (Paris); 1998 Apr 11; 30(4):123-4. PubMed ID: 9631694 [No Abstract] [Full Text] [Related]
17. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G. Curr Med Res Opin; 2004 Jul 11; 20(7):1103-14. PubMed ID: 15265255 [Abstract] [Full Text] [Related]
18. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, Ruiz NM, Ploughman LM, Labriola DF, Manion DJ. J Infect Dis; 2001 Feb 01; 183(3):392-400. PubMed ID: 11133370 [Abstract] [Full Text] [Related]
19. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M. N Engl J Med; 1995 Dec 21; 333(25):1662-9. PubMed ID: 7477218 [Abstract] [Full Text] [Related]
20. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P, Novavir Study Group. Antimicrob Agents Chemother; 2002 Jun 21; 46(6):1906-13. PubMed ID: 12019107 [Abstract] [Full Text] [Related] Page: [Next] [New Search]